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ABSTRACT 
The ulcerative colitis is a specific and non-specific inflammatory disease of large bowel, 
which is usually confined to its mucosa, presents with remissions and exacerbations where, the 
pathetical changes are usually restricted to mucosa except in very severe acute attacks of the disease 
when they reach into the deeper layers of the bowel wall. Colitis is an acute, subacute, or chronic 
disease of the colon and rectum of variable etiology, course and unpredictable prognosis. Bhaishajya 
Chikitsa is one of the treatment modalities of the Raktaatisar (ulcerative colitis) given by Ayurved 
literature which is also very effective like other treatment modalities. Also people have now turned 
their faith towards Ayurveda to resolve their health problems and hence most of cases perusable 
conservative treatment as it is more economical, painless, no hospitalization is required and no 
complications observed during or after medication.  
Modern medicine has limited source of medical treatment such as temporary medication 
with intestinal antibiotics, anti diarrhoeal, salazopyrine, steroids, immune modulator drugs and lastly 
surgery. Keeping all these facts in mind a clinical study was designed on the basis of 
Sampraptivighatana Chikitsha, for ulcerative colitis. Rasa Parpati & Jatyadi Ghrita having disease 
modifying potential and a good safely profile should thus be evaluated for use in this disease 
condition. The clinical study has been done on 60 patients, selected randomly and divided in two 
groups. Group A i.e trial group patients were treated with oral dose of Rasa Parpati & Jatyadi Ghrita 
Matra Basti. The Group B patients i.e. control group, were treated with Salazopyrine. The clinical 
assessment was done on the basis of clinical presentation of ulcerative colitis as well as colonoscopic 
findings, before and after the treatment. The findings of the study have been statistically analysed 
with the help of t-test and the result of the study found significant. 
KEY WORDS: Ulcerative Colitis, Rasa Parpati, Jatyadi Ghrita, Matra Basti, Colonoscopy Findings. 
INTRODUCTION 
The ulcerative colitis is a specific and non-
specific inflammatory disease of large bowel1, which is 
usually confined to its mucosa, presents with 
remissions and exacerbations where, the pathetical 
changes are usually restricted to mucosa except in very 
severe acute attacks of the disease when they reach 
into the deeper layers of the bowel wall. The disease 
doesn’t have a clearly known etiology; has been rarely 
affecting eastern population is now reported more 
commonly. Reports say it is affecting 10 -15 new 
people per 100,000 population every year; equally 
affecting both sexes; uncommon under 10 yrs. of age, 
most patients are between the age of 20 – 40 yrs. at 
diagnosis, but some of the authors say that ulcerative 
colitis is mostly affecting the age group between 20–39 
yrs, predominantly females2. 
Colitis is an acute, subacute, or chronic disease 
of the colon and rectum of variable etiology, course and 
unpredictable prognosis. Characterized by many local 
and systemic complications, cramping abdominal pain, 
anorexia, increased frequency of loose motions with 
mucous and blood, tenesmus and weight loss. The 
female to male ratio of ulcerative colitis is found to be 
4:3. As the civilization and materialization is increasing 
the incidence of ulcerative colitis is encountered more 
frequently in clinics, in modern medicine so many 
drugs are mentioned for treatment of ulcerative colitis 
like; sulfasalazine having both antibacterial and anti-
inflammatory properties.3 Glucocorticoids, purine 
analog compound, cytotoxic drugs, newer 
immunosuppressive agents and anti-tumor necrosis 
factors, etc. But, these drugs only control the episodes 
of the disease and not cure them; moreover these 
modern drugs have a huge list of possible side effects 
like intolerance and toxicity to other organs like liver, 
kidney, pancreas, eyes, etc. If we consider the surgical 
treatment of ulcerative colitis, it certainly gives better 
results but subsequently associated with massive 
complications like: change of lifestyle, change in 
dietary habits, and a colostomy with an external 
reservoir bag is a continuous psychological trauma to 
the patient in his social and personal life. Even if the 
continuity is restored with an ileorectal anastomosis 
there are fair chances of recurrence or with an ileoanal 
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anastomosis which lacks sphincter mechanism is 
associated with another set of complications4. 
Therefore, to avoid such complications and risks we 
need some other treatment modality. Keeping all these 
facts in mind a clinical study was designed on the basis 
of Sampraptivighatana Chikitsha, for ulcerative colitis. 
Rasa Parpati & Jatyadi Ghrita having disease modifying 
potential and a good safely profile should thus be 
evaluated for use of these drugs, in this disease 
condition. 
Aims & Objectives 
To study the etiological factors and 
pathogenesis of Ulcerative Colitis w.s.r. to Raktatisara 
in the influence of Ayurvedic and Modern parameters. 
To study the efficacy of Rasa Parpati with 
Jatyaadi Ghrita Matra Basti w.s.r. to Raktatisara with 
colonoscopy findings. 
To study the efficacy of Salazopyrine w.s.r. to 
Raktatisara with colonoscopy findings. 
MATERIALS & METHODS 
Materials 
Clinical study: The study will be carried out in OPD & 
IPD of Shalya-Tantra dept of S.V.N.H.T.Ayurved college 
Rahuri. The patient attending OPD / IPD will be 
selected of their age, sex, religion, race, occupation etc. 
Fulfilling the criteria of selection & eligibility for study.  
Plan of Study: Prior to the commencement of the 
therapy in the selected patients, general information 
both of the patients and the disease were made as 
below: 
A complete history of the disease along with 
complaints was recorded as per the specially designed 
proforma for ulcerative colitis disease with written 
consent of patient. 
Inclusive Criteria 
Those patients presenting with the clinical features 
like: 
1. Patients between age of 16 to 70 yrs. 
2. Diarrhea containing watery stool, mucous, blood & 
with/without pus in stool. 
3. Lower abdominal cramp 
4. Early morning spurious diarrhea 
5. Weakness 
6. Inspection – shows secondary fissures in the anal 
canal. 
7. On p/r examination, observed mucopus staining 
after withdrawal finger. 
8. On proctoscope examination in rectum observed 
superficial multiple small ulcers. 
9. Colonoscopy examination in colon observed 
superficial multiple small ulcers & change in 




Those patients presenting with the clinical features 
like: 
1. Patients below 16 and above 70 yrs. of age.  
2. Toxic megacolon 
3. Systemic manifestations like - arthritis, skin 
manifestations & iritis with corneal ulceration 
4. Hb%. Less than or equal to 5 mg/dl. 
5. Acute abdominal pain 
6. Stool frequency more than 15 per day 
7. Sign of Toxaemia 
8. Cancer 
9. Diabetes Mellitus 
10. HIV 
11. Tuberculosis 
12. Chronic diseases 
Investigations 
1. Routine Blood (Hb, TC, DC) 
2. Routine urine 
3. Stool examination for occult blood 
4. Colonoscopy 
5. Serum electrolyte (if necessary) 
6. Barium enema (if necessary) 
7. Biopsy  
Treatment Schedule: A total of 60 patients will be 
selected and treatment will be given in two groups. 
Group A: Patients will be given treatment as: 
1. Rasa Parpati5 
 Dose – 500mg  
 Anupana – Takra (Buttermilk)  
 Form of Medicine – Capsule form  
 Route of Administration – Oral route.  
 Time of administration – twice/daily  
 Duration of Treatment – 45 days  
 Follow up – weekly follow up of the patient 
presentations taken and colonoscopy is done 
every 15th day to appreciate the local changes in 
the colon mucosa. 
2. Jatyadi Ghrita6 
 Dose – 20ml  
 Form of Medicine – liquid  
 Route of Administration – per rectal.  
 Time of administration – once daily  
 Duration of Treatment – 45 days 
 Follow up – weekly follow up of the patient 
presentations taken and colonoscopy is done 
every 15th day to appreciate the local changes in 
the colon mucosa. 
Matra Basti Procedure 
Equipments 
 Red rubber catheter 
 Dispovan syringe of 50 ml 
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 Cotton pads. 
 Luke warm Jatyadi Ghrita 
 Surgical gloves 
Pre-operative 
 If the patient got an urge to defecate, then he is 
asked to defecate first and then the procedure is 
started.  
 Massage over lumber region using tila taila for 5 
mins. 
 Fomentation done by keeping a towel dipped in 
warm water over the lumer region for 5 mins. 
Procedure 
 Patient should lie in left lateral position. 
 Retraction of the buttocks to expose the anal 
opening. 
 Lubricate the tip of the red rubber catheter with 
the Jatyadi Ghrita. 
 The tip is slowly inserted in the anus upto the 
rectum. 
 The loaded syringe (with Jatyadi Ghrita) is 
approximated to the tail of the catheter. 
 Jatyadi Ghrita is slowly and continuously injected 
into the rectum. 
 Now, the rubber catheter is slowly removed and 
cotoon pad is placed over the anal opening. 
Post-operative 
 Head low position is given to the patient lasting 
for 30 mins. 
 If patient desires to defecate then, he is asked to 
avoid the urge. 
 Patient is allowed to conduct his regular activities 
after 30 mins. 
Group B: Patients will be given treatment as:  
Salazopyrine7  
 Dose – 500mg  
 Form of Medicine – Tablet form  
 Route of Administration – Oral route.  
 Time of administration – twice/daily  
 Duration of Treatment – 45 days 
 Follow up – weekly follow up of the patient 
presentations taken and colonoscopy is done 
every 15th day to appreciate the local changes in 
the colon mucosa 
Follow Up Study 
The patients of OPD have checked up weekly once 
and the changes have observed and documented for 
analysis. The colonoscopy is performed very 15th day.  
 On day ‘0’ to assess the before treatment 
presentation of the colon. 
 On day ‘15’ & ‘30’ during the procedure to look for 
the effects of drug on colon 
 On day ‘45’ to assess the after treatment 
presentation i.e. the overall effect of the therapy 
on 1 patient. 
 
 
Criteria of Assessment 
The treatment effect has been assessed on the 
basis of the relief in signs and symptoms of the disease. 
This was done on every follow up day at OPD level and 
Colpnoscopy was performed on alternate follow up 
days. Scoring pattern was adopted to determine the 
relief in the cardinal symptom 
Diarrhoea 
0 - No diarrhea 
1 - Diarrhea with <4 frequency & Consistency dome. 
2 - Diarrhea with <6 frequency& Consistency semi 
liquid. 
3 - Diarrhea with 10 frequency & Consistency semi 
liquid. 
4 - Diarrhea with <10 frequency & Consistency semi 
liquid. 
 Mucin Discharge 
0 - Absent  
1 - Mild (less quantity of mucous with more stool). 
2 - Moderate (equal quantities of mucous & stool). 
3 - Severe (more quantity of mucous with less stool). 
Bleeding P/R 
0 - Absent  
1 - Mild (occult blood with Hb. 10g/dl) 
2 - Moderate (stool color red with Hb. 8g/dl) 
3 - Severe (blackish stool with Hb. <8g/dl) 
Abdominal pain 
0 - No pain  
1 - Pain lasting for 15 min  
2 - Pain lasting for 15 to 45 mins 
3 - Continuous pain 
Weakness 
0 - No weakness 
1 - Weakness after work for 2 hrs. 
2 - Weakness after work for 1 hr. 
3 - Weakness after work for 30 mins. 
Anaemia 
0 - No anaemia 
1 - Hb less than 10 mg/dl 
2 - Hb less than 8 mg/dl 
3 - Hb less than 6 mg/dl 
Tenesmus 
0 - No tenesmus 
1 - 2 to 3 times a day 
2 - 4 to 5 times a day 
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3 - 5 to 6 times a day 
Loss of weight 
0 - No weight loss  
1 - 5 % of the body weight 
3 - 15 % of the body weight 
4 - More than 15 % of the body weight 
Colonoscopy findings 
2 - 10 % of the body weight  
0 - Normal & healthy colon mucosa 
1 - Mucosa is erythematous and granular. Superficial 
ulceration may be seen. 
2 - Diffuse haemorrhagic inflammation with patches of 
exudates and microscopic ulcers may be seen. 
3 - Pseudopolyposis (ulcers surrounded by heaped 
upareas of granulation tissue & edematous mucosa) 
with removable contracted lumen of rectosigmoid. 
4 - Ulcerative colitis with carcinoma of the colon as 
reported by biopsy investigation of the tumor in the 
colon mucosa 
Results obtained are assessed as 
1. Incurable  :  less than 25 % 
2. Improved   : 25% to 50% 
3. Markedly Improved : 50% to 75% 
4. Cured   : more than 75% 
5. LAMA  : left against medical 
advice 
RESULTS  
Table 1: Effect of Therapy on Cardinal Symptoms of Ulcerative colitis in Group A 
Table 2 : Effect of Therapy on Cardinal Symptoms of Ulcerative colitis in Group B 
 




S.D. S.E. ‘t’ cal.  p value Result % of 
Relief 
Loose Stools (frequency) 
{Atisar} 
30 2.23 0.66 0.50 0.091 17.14 P<0.001 H.S 70 
Mucin discharge 
{Picchilastrav}  
30 1.53 0.70 0.46 0.08 10.37 P<0.001 H.S 54 
Bleeding P/R {Gudagata 
Raktastrav} 
21 1.19 0.23 0.38 0.082 11.58 P<0.001 H.S 80 
Abdominal pain {Udarshula} 30 1.3 0.56 0.44 0.08 9.12 P<0.001 H.S 56 
Nausea & Vomiting {Hrullas & 
Chardi} 
11 1.09 0 0.30 0.09 12.11 P<0.001 H.S 100 
Weakness {Dourbalya} 30 1.46 0.56 0.30 0.05 18 P<0.001 H.S 61 
Anaemia {Pandu} 17 1.29 1 1.49 0.11 3.18 P<0.01 H.S 22 
Tenesmus  {Prawahana} 30 1.53 0.43 0.30 0.05 22 P<0.001 H.S 71 
Loss of weight 29 1.51 1.13 0.62 0.11 3.36 P<0.01 H.S 25 
Colonoscopy findings of the 
colon. 
30 1.56 0.83 0.43 0.07 10.58 P<0.001 H.S 46 




S.D. S.E. ‘t’ cal.  p value Result % Of 
Relief 
Loose Stools (frequency) 
{Atisar} 
30 2.3 0.46 0.85 0.15 12.2 P<0.001 H.S 79 
Mucin discharge 
{Picchilastrav}  
30 1.53 0.30 0.63 0.11 10.90 P<0.001 H.S 80 
Bleeding P/R  
{Gudagata Raktastrav} 
29 1.55 0.17 0.56 0.10 13.70 P<0.001 H.S 88 
Abdominal pain {Udarshula} 30 1.83 0.03 0.92 0.16 11.25 P<0.001 H.S 98 
Nausea & Vomiting  
{Hrullas & Chardi} 
12 1.08 0 0.28 0.08 13.50 P<0.001 H.S. 100 
Weakness {Dourbalya} 30 1.96 0.66 0.59 0.10 13 P<0.001 H.S 66 
Anaemia {Pandu} 17 1.64 1.23 0.50 0.12 3.41 P<0.01 H.S 25 
Tenesmus {Prawahana} 30 1.96 0.3 0.69 0.12 13.33 P<0.001 H.S 84 
Loss of weight 28 1.71 1.17 0.50 0.09 5.88 P<0.001 H.S 31 
Colonoscopy findings of the 
colon. 
30 1.66 1.03 0.55 0.10 6.3 P<0.001 H.S 38 
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OVERALL EFFECT OF THERAPY 
Table 3: Overall effect of Therapy in Group A 
Effect No of Pt. Percentage (%) 
Cured 03 10 
Markedly Improved 18 60 
Improved 09 30 
Incurable 0 0 
 
Table 4: Overall effect of Therapy in Group B 
Effect No of Pt. Percentage (%) 
Cured 04 13.33 
Markedly Improved 26 86.66 
Improved 0 0 
Incurable 0 0 
DISCUSSION 
Mode of Action of Rasa Parpati 
Rasa Parpati is useful in patients of 
Raktatisara (ulcerative colitis) by, enhancing the 
normal functioning of Pakwashaya due to its 
Rasayana property and Gamitwa towards Pittadhara 
Kala. Parpati has an important place in Rasa Kalpas, 
it is obtained in the form of flakes, gets disintegrated 
in the body at the level of Grahanidhara Kala. Hence 
it is specifically being used in Grahani related 
disorders like Raktatisara and Pittatisara and also 
effective in correcting appetite. Its mode of action is 
such that the Agni gets locked in the Parpati Kalpa 
making it to act best in disorders related to 
Agnimandya. The dose form is such that it doesn’t act 
in the stomach, instead starts its action in the 
duodenum and onwards. 
 As described by Bhaishajya Ratnavali in the 
chapter of Sangrahani Rogaadhikar, Parpati acts on 
digestive system as Doshaghna, Jantughna and  
Balya. It settles the irritation and inflammation of 
colon mucosa by reducing laxity. The Rasa Parpati 
containing Shuddha Parada and Shuddha Gandhaka 
acts like Sanjeevani for all abdominal disorders like 
ulcerative colitis & other G.I. disorders. It helps to 
improve Grahana Karya of intestines thus, reducing 
complaints of Atisara (frequency). During the 
preparation of Rasa Parpati cow dung cakes are used 
which consists of Gopitta. The Rasa Parpati gets 
Samskara of Gopitta and attains Dipana-Pachana 
property and therefore causes Agnidipana and 
Amapachana which is desired in Raktatisara and 
Pittatisara.  
The Rasa Parpati also helps in proper 
secretion of digestive juices causing correction of 
digestion; enhances absorption of nutrients & 
minerals and therefore, provides Bala and reduces 
malnutrition. 
Mode of Action of Jatyadi Ghrita 
The Jatyadi Ghrita has Shodhana and 
Ropana properties. It reduces inflammation by its 
Shodhana property and also by its anti-microbial 
property, and therefore, reduces pain by minimizing 
the inflammation of the colon mucosa and 
simultaneously reduces Srava (mucin discharge). 
The Jatyadi Ghrita has Nimba as content, Nimba is 
Krimighna by its Prabhava and hence possess anti 
microbial activity in ulcerative colitis. 
Given in the form of Basti, the Jatyadi Ghrita 
acts locally over the colon mucosa, causes Shodhana 
of Pittadhara Kala, enhances Shoshana of Ahararasa 
and therefore, reduces malnutrition and 
simultaneously minimizes weakness. The oily and 
sticky property of the Jatyadi Ghrita keeps the 
wound surface wet and thereby, facilitates healing of 
ulcers by its best Vranaropaka property. Also its 
Raktastambhana property provides haemostasis and 
thereby, reduces bleeding and occult blood loss in 
stool. 
CONCLUSION 
 Rasa Parpati & Jatyadi Ghrita show significant 
effect on Diarrhoea, Mucin discharge, Bleeding 
P/R, Abdominal pain, Nausea & Vomiting, 
Weakness, Anaemia, Tenesmus, Loss of weight and 
Colonoscopy findings. 
 Basti Medicament containing Jatyadi Ghrita for its 
local effect has shown, improvement or cure of the 
ulcerations of the bowel by enhanced healing and 
subsiding inflammation & irritability of the colon. 
 It also improves functions of Apana Vayu, situated 
in Pakwashaya and results into improvement of 
ulcerations and regulation of evacuation of the 
colon. 
 Since, ulcerative colitis is an incurable disease and 
need to be maintained lifelong with palliative 
measures like steroids and anti inflammatory 
drugs. For a disease of short duration, use of the 
drugs having side effects can be neglected 
considering its much greater contribution in 
curing the disease, but, a disease like ulcerative 
colitis in particular; treatment has to be given for 
the whole life where the massive side effects of 
steroid therapy cannot be overlooked. 
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 For such a diseases, the role of Ayurvedic therapy 
is very vital, as Rasa Parpati & Jatyadi Ghrita show 
very minimal or no side effects and has been 
proved effective in limiting the symptoms of 
ulcerative colitis, in the present study. 
 Considering Surgical management, the only option 
a patient of colitis is left with; is to undergo a pan-
colectomy with abdomino-perineal resection of 
the whole large bowel including the rectum and 
finally a colostomy which is very uncomfortable in 
the personal as well as social life of the patient and 
as evident by the history of such patients, carrying 
a colostomy bag and maintenance of its hygiene is 
a continuous mental trauma to the patient. 
 An attempt has been made to minimize these 
colostomy associated complications, with an 
alternative of ileo-rectal anastomosis with ileal 
pouching (making an ileal reservoir to delay 
evacuation period) but this particular surgery is 
also under controversy. 
 Keeping in mind these complications of surgical 
management, this Ayurvedic therapy is definitely a 
better option.  
 The Rasa Parpati was administered in the form of 
capsules, which has increased the palatability of 
the drug and also prevents nausea and vomiting in 
a few patients because of its unpleasant and 
unacceptable taste. This preparation of Rasa 
Parpati in the form of capsules is modernization of 
Ayurvedic treatment and route of administration.  
 The treatment with Rasa Parpati & Jatyadi Ghrita 
for the duration of 45 days shows marked relief in 
some patients and mild or moderate relief in some 
patients, depending upon the presentation and 
chronicity of the disease. 
 In a few number of patients continuation of the 
therapy for a longer duration may show even 
better results on colitis. 
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1. DRUG PHOTOGRAPHS 
 
   
      Figure 1: Preparation of Rasa Parpati        Figure 2: Prepared Rasa Parpati 
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2. CLINICAL PROCEDURES 
 
             
               Figure 5: Video Colonoscope           Figure 6: Colonoscopy Procedure    
 
              
       Figure 7: Requirements of Matra Basti     Figure 8: Matra Basti Procedure       
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3. PHOTOGRAPHS OF COLONOSCOPY FINDIGS 
Colonoscopy Findings in Group A (Treated with Rasa Parpati & Jatyadi Ghrita)  
   
       Figure 5: (a). Before Treatment   Figure 6: (b). After Treatment 
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Colonoscopy Findings in Group B (treated with Salazopyrine) 
   
         Figure 9: Before Treatment      Figure 10: After Treatment 
 
    
        Figure 11: Before Treatment    Figure 12: After Treatment 
 
 
 
 
